Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients: Chronic Myeloproliferative Disorders

Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients: Chronic Myeloproliferative Disorders

The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such complications was studied in 126 subjects diagnosed with ET at a median age of 31 years (range: 5–40). Overa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2007, Vol.21 (6), p.1218-1223
Hauptverfasser: Alvarez-Larrán, A, Cervantes, F, Bellosillo, B, Giralt, M, Juliá, A, Hernández-Boluda, J C, Bosch, A, Hernández-Nieto, L, Clapés, V, Burgaleta, C, Salvador, C, Arellano-Rodrigo, E, Colomer, D, Besses, C
Format: Artikel
Sprache:eng
Schlagworte:
Cancer Research
Critical Care Medicine
Hematology
Intensive
Internal Medicine
Medicine
Medicine & Public Health
Oncology
original-article
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such complications was studied in 126 subjects diagnosed with ET at a median age of 31 years (range: 5–40). Overall survival and probability of survival free of thrombosis, bleeding and MF were analyzed by the Kaplan–Meier method and the presence of the Janus Kinase 2 (JAK2) V617F mutation correlated with the appearance of such complications. The JAK2 mutation (present in 43% of patients) was associated with higher hemoglobin (Hb) ( P
ISSN:0887-6924
1476-5551
DOI:10.1038/sj.leu.2404693